Travere Therapeutics' Filspari Nears, But Misses, Primary Endpoint in IgA Nephropathy Trial
核心洞察
Travere Therapeutics' Filspari narrowly missed statistical significance in a Phase 3 trial for IgA nephropathy (搜索), a rare kidney disorder, with a p-value of 0.058.
The trial involved 404 patients randomized to receive Filspari or irbesartan, an existing blood pressure medication used to manage the disease.
While early data showed a 50% reduction in urine protein levels, the 24-month data on kidney function decline narrowly missed the primary endpoint.
Travere Therapeutics announced that its confirmatory Phase 3 trial evaluating Filspari (sparsentan) for IgA nephropathy (搜索) (IgAN) narrowly missed its primary endpoint. The study, involving 404 patients, compared Filspari to irbesartan, a commonly used blood pressure medication in managing IgAN. While the data indicated a slower decline in kidney function among patients receiving Filspari over 24 months, the results fell just short of statistical significance (p=0.058).
Trial Design and Results
The Phase 3 trial randomized patients with IgAN to either Filspari, a daily oral medication, or irbesartan. The primary endpoint assessed the change in estimated glomerular filtration rate (eGFR) over 24 months. Secondary endpoints included proteinuria reduction and safety assessments. Initial data, which led to accelerated approval in February, demonstrated a 50% reduction in proteinuria, a key biomarker of kidney function, after nine months of treatment. However, the 24-month data on eGFR, a more direct measure of kidney function, did not achieve the pre-specified level of statistical significance.
Clinical Context and Implications
IgA nephropathy (搜索) is a rare kidney disease characterized by the buildup of immunoglobulin A (IgA) in the kidneys, leading to inflammation and potential kidney damage. Current treatment strategies often involve managing blood pressure and reducing proteinuria. The accelerated approval of Filspari was based on its ability to reduce proteinuria, a surrogate marker for kidney function. The full approval was contingent upon demonstrating a statistically significant benefit on kidney function decline in the confirmatory trial. The company will now need to discuss the implications of these results with regulatory authorities.